cognitive cybersecurity intelligence

News and Analysis


Sparsentan may be a new treatment option for focal segmental glomerulosclerosis

Sparsentan, a medication, may be a potential new treatment option for Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disorder that can lead to kidney failure. A University of Minnesota Medical School-led study found that FSGS patients treated with sparsentan showed improved kidney function and displayed significant reductions in proteinuria.

Source: –

Subscribe to newsletter

Subscribe to HEAL Security Dispatch for the latest healthcare cybersecurity news and analysis.

More Posts